Age and Hepatitis C Increase Risk of Diabetes for Hemophilia Patients
Diabetes, which causes blood sugar levels to rise too high, is less likely to develop in young men with…
Articles by Margarida Maia, PhD
Four Cases of Acquired Hem A Reported After 2nd COVID-19 Vaccine
Four people in a region of Northern Italy were diagnosed with acquired hemophilia A (AHA) weeks after receiving the second dose…
High COVID-19 Vaccination Rates, But Concerns, for Austrian Patients
In Austria, most patients with hemophilia have been vaccinated against COVID-19 — but some expressed concerns over the vaccine’s…
FLT180a for Hemophilia B Keeps Normal Factor IX Levels for 3+ Years
In a Phase 1/2 dose-finding study called B-AMAZE, FLT180a gene therapy from Freeline Therapeutics brought about sustained levels of…
Patients Express Gains in Switch to Extended Half-life Therapies
For some patients with moderate or severe hemophilia, switching from standard to extended half-life replacement therapy results in improvements…
Long-term Preventive Use of Esperoct Effective in Hemophilia A
Long-term prophylactic (preventive) treatment with a fixed dose of Esperoct (turoctocog alfa pegol) — approved in the U.S. and…
Females Account for 1 in 5 Mild Hemophilia Cases at US Centers
Nearly one-fifth of patients with mild hemophilia admitted to treatment centers in the U.S. are female, according to a…
Hemophilia Carriers Voice Need for Better Pregnancy, Childbirth Care
Women who are carriers for hemophilia — meaning they can pass the disease-causing mutation to their children — think a…
SCT800 Seen as Safe, Effective for Hemophilia A in Phase 3 Trial
SCT800, a replacement therapy containing a man-made form of clotting factor VIII (FVIII), appears to be safe and effective…
Voncento Safe, Effective in Young Children With Hemophilia A, Trial Finds
Voncento — a highly concentrated mixture of Von Willebrand factor (VWF) and clotting factor VIII (FVIII) — was seen to…